200 related articles for article (PubMed ID: 17998390)
21. Genomic instability in B-cells and diversity of recombinations that activate c-myc.
Janz S; Jones GM; Müller JR; Potter M
Curr Top Microbiol Immunol; 1995; 194():373-80. PubMed ID: 7895512
[TBL] [Abstract][Full Text] [Related]
22. Functional homology between N-myc and c-myc in murine plasmacytomagenesis: plasmacytoma development in N-myc transgenic mice.
Wang Y; Sugiyama H; Axelson H; Panda CK; Babonits M; Ma A; Steinberg JM; Alt FW; Klein G; Wiener F
Oncogene; 1992 Jun; 7(6):1241-7. PubMed ID: 1375720
[TBL] [Abstract][Full Text] [Related]
23. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
24. Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes.
Kato L; Begum NA; Burroughs AM; Doi T; Kawai J; Daub CO; Kawaguchi T; Matsuda F; Hayashizaki Y; Honjo T
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2479-84. PubMed ID: 22308462
[TBL] [Abstract][Full Text] [Related]
25. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
26. Absence of Activation-induced Cytidine Deaminase, a Regulator of Class Switch Recombination and Hypermutation in B Cells, Suppresses Aorta Allograft Vasculopathy in Mice.
Nakanishi T; Xu X; Wynn C; Yamada T; Pan F; Erickson L; Teo H; Nakagawa T; Masunaga T; Abe J; Akamatsu M; Tamura K; Jiang H
Transplantation; 2015 Aug; 99(8):1598-605. PubMed ID: 25769064
[TBL] [Abstract][Full Text] [Related]
27. An exceptional mouse plasmacytoma with a new kappa/N-myc [T(6; 12) (C1; B)] translocation expresses N-myc but not c-myc.
Silva S; Wang Y; Babonits M; Axelson H; Wiener F; Klein G
Curr Top Microbiol Immunol; 1992; 182():251-9. PubMed ID: 1490362
[TBL] [Abstract][Full Text] [Related]
28. Combined deletion of Xrcc4 and Trp53 in mouse germinal center B cells leads to novel B cell lymphomas with clonal heterogeneity.
Chen Z; Elos MT; Viboolsittiseri SS; Gowan K; Leach SM; Rice M; Eder MD; Jones K; Wang JH
J Hematol Oncol; 2016 Jan; 9():2. PubMed ID: 26740101
[TBL] [Abstract][Full Text] [Related]
29. The block in immunoglobulin class switch recombination caused by activation-induced cytidine deaminase deficiency occurs prior to the generation of DNA double strand breaks in switch mu region.
Catalan N; Selz F; Imai K; Revy P; Fischer A; Durandy A
J Immunol; 2003 Sep; 171(5):2504-9. PubMed ID: 12928399
[TBL] [Abstract][Full Text] [Related]
30. A new variant 15; 16 translocation in mouse plasmacytoma leads to the juxtaposition of c-myc and immunoglobulin lambda.
Axelson H; Panda CK; Silva S; Sugiyama H; Wiener F; Klein G; Sumegi J
Oncogene; 1991 Dec; 6(12):2263-70. PubMed ID: 1766673
[TBL] [Abstract][Full Text] [Related]
31. A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.
Kotani A; Okazaki IM; Muramatsu M; Kinoshita K; Begum NA; Nakajima T; Saito H; Honjo T
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4506-11. PubMed ID: 15767564
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice.
Jiang C; Foley J; Clayton N; Kissling G; Jokinen M; Herbert R; Diaz M
J Immunol; 2007 Jun; 178(11):7422-31. PubMed ID: 17513793
[TBL] [Abstract][Full Text] [Related]
33. The "missing" mouse plasmacytoma (MPC) associated translocation T(15;16) occurs repeatedly in new MPC induction systems.
Wiener F; Silva S; Sugiyama H; Babonits M; Klein G
Genes Chromosomes Cancer; 1990 May; 2(1):36-43. PubMed ID: 2126192
[TBL] [Abstract][Full Text] [Related]
34. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
35. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Gabrea A; Martelli ML; Qi Y; Roschke A; Barlogie B; Shaughnessy JD; Sawyer JR; Kuehl WM
Genes Chromosomes Cancer; 2008 Jul; 47(7):573-90. PubMed ID: 18381641
[TBL] [Abstract][Full Text] [Related]
36. Tissue-specific sensitivity to AID expression in transgenic mouse models.
Rucci F; Cattaneo L; Marrella V; Sacco MG; Sobacchi C; Lucchini F; Nicola S; Della Bella S; Villa ML; Imberti L; Gentili F; Montagna C; Tiveron C; Tatangelo L; Facchetti F; Vezzoni P; Villa A
Gene; 2006 Aug; 377():150-8. PubMed ID: 16787714
[TBL] [Abstract][Full Text] [Related]
37. Location of Myc, Igh, and Igk on Robertsonian fusion chromosomes is inconsequential for Myc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors prefer Igk-Myc inversions over translocations.
Silva S; Wiener F; Klein G; Janz S
Genes Chromosomes Cancer; 2005 Apr; 42(4):416-26. PubMed ID: 15645495
[TBL] [Abstract][Full Text] [Related]
38. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
39. AID targeting in antibody diversity.
Pavri R; Nussenzweig MC
Adv Immunol; 2011; 110():1-26. PubMed ID: 21762814
[TBL] [Abstract][Full Text] [Related]
40. C-myc-S mu rearrangement in a murine plasmacytoma without visible chromosomal translocations.
Ohno S; Migita S; Murakami S
Oncogene; 1989 Dec; 4(12):1513-7. PubMed ID: 2687771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
